<strong>DMD</strong> <strong>#048264</strong> Acknowledgements We thank Christoph Funk <strong>and</strong> Wanping Geng from Non-Clinical Safety, Roche Pharma Research <strong>and</strong> Early Development for critical reading <strong>of</strong> the manuscript <strong>and</strong> Jian Xin, Hongxia Qiu, <strong>and</strong> Sheng Zhong from Non-Clinical Safety, Roche Pharma Research <strong>and</strong> Early Development China for helpful discussion on study design. Authorship Contribution Participated in research design: Ren, Yan, Fei, <strong>and</strong> Chen Conducted experiments: Ren <strong>and</strong> Zeng Contributed new reagents or analytic tools: Ren Performed data analysis: Ren <strong>and</strong> Zeng Wrote or contributed to the writing <strong>of</strong> the manuscript: Ren, Yan, Zeng, Mei, Zhang, Fei, <strong>and</strong> Chen 28
<strong>DMD</strong> <strong>#048264</strong> References Baron A, Frieden M, <strong>and</strong> Bény JL (1997) Epoxyeicosatrienoic acids activate a highconductance, Ca(2+)-dependent K+ channel on pig coronary artery endothelial cells. J Physiol 504: 537-543. Batsanov SS (2001) van der Waals radii <strong>of</strong> elements. Inorg Mater 37: 871-885. Bayly CI, Cieplak P, Cornell W, <strong>and</strong> Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem 97: 10269–10280. Berry LM <strong>and</strong> Zhao Z (2008) An examination <strong>of</strong> IC50 <strong>and</strong> IC50-shift experiments in assessing time-dependent inhibition <strong>of</strong> CYP3A4, CYP2D6 <strong>and</strong> CYP2C9 in human liver microsomes. Drug Metab Lett 2: 51-59. Bialer M (1993) Comparative pharmacokinetics <strong>of</strong> the newer antiepileptic drugs. Clin Pharmacokinet 24: 441-452. Bondi A (1964) van der Waals volumes <strong>and</strong> radii. J Phys Chem 68: 441–451. Brash AR (2010) Arachidonic acid as a bioactive molecule. J Clin Invest 107: 1339- 1345. Capdevila JH, Falck JR, <strong>and</strong> Harris RC (2000) Cytochrome P450 <strong>and</strong> arachidonic acid bioactivation. Molecular <strong>and</strong> functional properties <strong>of</strong> the arachidonate monooxygenase. J Lipid Res 41: 163-181. Case DA, Cheatham TE, III, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B, <strong>and</strong> Woods RJ (2005) The AMBER biomolecular simulation programs. J Comput Chem 26: 1668-1688. Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, <strong>and</strong> Wang DW (2009) Selective inhibitors <strong>of</strong> CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro <strong>and</strong> in vivo. J Pharmacol Exp Ther 329: 908-918. Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, <strong>and</strong> Wang DW (2011) Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases <strong>and</strong> promotes tumor cell growth. J Pharmacol Exp Ther 336: 344-355. Connolly ML (1983) The contribution <strong>of</strong> halogen atoms to protein-lig<strong>and</strong> interactions. J Appl Crystallogr 16: 548-558. Darden T, York D, <strong>and</strong> Pedersen L (1993) Particle mesh Ewald: an N.log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, <strong>and</strong> Goldstein JA (2007) Detection <strong>of</strong> human CYP2C8, CYP2C9, <strong>and</strong> CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35: 682-688. Deppe S, Böger RH, Weiss J, <strong>and</strong> Benndorf RA (2010) Telmisartan: a review <strong>of</strong> its pharmacodynamic <strong>and</strong> pharmacokinetic properties. Expert Opin Drug Metab Toxicol 6: 863-710. Ding X <strong>and</strong> Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism <strong>and</strong> tissue-selective chemical toxicity in the respiratory <strong>and</strong> gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43: 149-173. 29
- Page 1 and 2: DMD Fast Forward. Published on Octo
- Page 3 and 4: DMD #048264 Abstract Cytochrome P45
- Page 5 and 6: DMD #048264 its rather broad substr
- Page 7 and 8: DMD #048264 role of CYP2J2 in drug
- Page 9 and 10: DMD #048264 CYP2C9, CYP2C19, and CY
- Page 11 and 12: DMD #048264 AST, DES-AST, and IS, r
- Page 13 and 14: DMD #048264 where v is the reaction
- Page 15 and 16: DMD #048264 = ΔEelec + ΔEvdW + Δ
- Page 17 and 18: DMD #048264 Paine et al., 2006) and
- Page 19 and 20: DMD #048264 plot does not go throug
- Page 21 and 22: DMD #048264 surface for telmisartan
- Page 23 and 24: DMD #048264 given its predominant e
- Page 25 and 26: DMD #048264 subsequently confirmed
- Page 27: DMD #048264 activity by restraining
- Page 31 and 32: DMD #048264 Lafite P, Dijols S, Zel
- Page 33 and 34: DMD #048264 Young CL, Dias VC, and
- Page 35 and 36: DMD #048264 Figure Legends FIGURE 1
- Page 37 and 38: DMD #048264 segment (Ile376, Pro377
- Page 39 and 40: DMD #048264 Table 2: Probe substrat
- Page 41: DMD #048264 Table 4: Binding free e